Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8232783 | 0.92 | ADORA1 (0.43) | ADORA1GPR119MEN1KMT2AALDH1A1 | |
| SCHEMBL5731159 | 0.91 | ADORA1 (0.47) | ADORA1ESR2NR1H2GPR119MEN1 | |
| SCHEMBL23040402 | 0.90 | ADORA1 (0.40) | ADORA1GPR119MEN1KMT2AALDH1A1 | |
| SCHEMBL12243830 | 0.88 | ADORA1 (0.49) | ADORA1ESR2NR1H2GPR119MEN1 | |
| SCHEMBL951903 | 0.88 | NR1H2 (0.42) | ADORA1ESR2NR1H2SMN1; SMN2STS | |
| SCHEMBL3992432 | 0.88 | ADORA1 (0.37) | ADORA1MEN1KMT2AALDH1A1GAA | |
| SCHEMBL1082333 | 0.86 | ESR1 (0.39) | ADORA1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL4298228 | 0.86 | ADORA1 (0.43) | ADORA1ESR2NR1H2GPR119SMN1; SMN2 | |
| SCHEMBL30340774 | 0.84 | HTT (0.37) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL13382352 | 0.83 | ESR2 (0.41) | ADORA1ESR2NR1H2GPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | claimed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2367821-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | claimed |
| EP-4562000-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119630652-A | Amino heteroaryl kinase inhibitors | 安锐生物医药公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2025007074-A1 | CHEMICAL COMPOUNDS | REACTIVE BIOSCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
| EP-1372653-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7015235-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | GOULET MARK T | 2006-02-16 | — | — | US | disclosed |
| EP-1372653-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-20 | — | — | US | disclosed |
| EP-1372653-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002068387-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | ADORA1 4570/4885ESR2 2087/4885NR1H2 1773/4885 |
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | ADORA1 1191/4885ESR2 1268/4885NR1H2 1553/4885 |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | ADORA1 237/4885ESR2 748/4885NR1H2 1215/4885 |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | ADORA1 237/4885ESR2 748/4885NR1H2 1215/4885 |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | ADORA1 1191/4885ESR2 1268/4885NR1H2 1553/4885 |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | PRKCB, PNCK, PACSIN2 | ADORA1 4509/4885ESR2 2053/4885NR1H2 3097/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | ADORA1 1880/4885ESR2 1772/4885NR1H2 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.